Cargando…

Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience

BACKGROUND: Peri-operative radiation of retroperitoneal sarcomas (RPS) is an important component of multidisciplinary treatment. All retrospective series thus far included patients treated with older radiation therapy (RT) techniques including 2D and 3DRT. Intensity modulated radiation therapy (IMRT...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosper, Pippa F., Olsen, Jeffrey, DeWees, Todd, Van Tine, Brian A., Hawkins, William, Michalski, Jeff, Zoberi, Imran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721605/
https://www.ncbi.nlm.nih.gov/pubmed/29216884
http://dx.doi.org/10.1186/s13014-017-0920-y
_version_ 1783284841910894592
author Cosper, Pippa F.
Olsen, Jeffrey
DeWees, Todd
Van Tine, Brian A.
Hawkins, William
Michalski, Jeff
Zoberi, Imran
author_facet Cosper, Pippa F.
Olsen, Jeffrey
DeWees, Todd
Van Tine, Brian A.
Hawkins, William
Michalski, Jeff
Zoberi, Imran
author_sort Cosper, Pippa F.
collection PubMed
description BACKGROUND: Peri-operative radiation of retroperitoneal sarcomas (RPS) is an important component of multidisciplinary treatment. All retrospective series thus far included patients treated with older radiation therapy (RT) techniques including 2D and 3DRT. Intensity modulated radiation therapy (IMRT) allows for selective dose escalation while sparing adjacent organs. We therefore report the first series of patients with RPS treated solely with IMRT, surgery and chemotherapy. We hypothesized that IMRT would permit safe dose escalation and superior rates of local control (LC) in this high-risk patient population. METHODS: Thirty patients with RPS treated with curative intent between 2006 and 2015 were included in this retrospective study. RT was administered either pre- or post-operatively and IMRT was used in all patients. Statistical comparisons, LC, distant metastasis (DM), and overall survival (OS) were calculated by Kaplan-Meier analysis and univariate Cox regression. RESULTS: Median follow-up time after completion of RT was 36 months (range 1.4-112). Median tumor size was 14 cm (range 3.6 - 28 cm). The most prevalent histologies were liposarcoma in 10 (33%) patients and leiomyosarcoma in 10 (33%) with 21 patients (70%) having high-grade disease. Twenty-eight (93%) patients had surgical resection with 47% having positive margins. Chemotherapy was administered in 9 (30%) patients. RT was delivered pre-operatively in 11 (37%) patients, and post-operatively in 19 (63%) with 60% of patients receiving a simultaneous integrated boost. Pre-operative median RT dose to the high-risk area was 55 Gy (range, 43–66 Gy) while median post-operative dose was 60.4 Gy (range, 45-66.6 Gy). There was one acute grade 3 and one late grade 3 toxicity and no grade 4 or 5 toxicities. Three year actuarial LC, freedom from DM, and OS rates were 84%, 64%, and 68% respectively. Positive surgical margins were associated with a higher risk of local recurrence (p = 0.02) and decreased OS (p = 0.04). Pre-operative RT was associated with improved LC (p = 0.1) with a 5-year actuarial LC of 100%. Administration of chemotherapy, timing of RT, histology or grade was not predictive of OS. CONCLUSIONS: Patients with RPS treated with peri-operative IMRT at our institution had excellent local control and low incidences of toxicity.
format Online
Article
Text
id pubmed-5721605
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57216052017-12-12 Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience Cosper, Pippa F. Olsen, Jeffrey DeWees, Todd Van Tine, Brian A. Hawkins, William Michalski, Jeff Zoberi, Imran Radiat Oncol Research BACKGROUND: Peri-operative radiation of retroperitoneal sarcomas (RPS) is an important component of multidisciplinary treatment. All retrospective series thus far included patients treated with older radiation therapy (RT) techniques including 2D and 3DRT. Intensity modulated radiation therapy (IMRT) allows for selective dose escalation while sparing adjacent organs. We therefore report the first series of patients with RPS treated solely with IMRT, surgery and chemotherapy. We hypothesized that IMRT would permit safe dose escalation and superior rates of local control (LC) in this high-risk patient population. METHODS: Thirty patients with RPS treated with curative intent between 2006 and 2015 were included in this retrospective study. RT was administered either pre- or post-operatively and IMRT was used in all patients. Statistical comparisons, LC, distant metastasis (DM), and overall survival (OS) were calculated by Kaplan-Meier analysis and univariate Cox regression. RESULTS: Median follow-up time after completion of RT was 36 months (range 1.4-112). Median tumor size was 14 cm (range 3.6 - 28 cm). The most prevalent histologies were liposarcoma in 10 (33%) patients and leiomyosarcoma in 10 (33%) with 21 patients (70%) having high-grade disease. Twenty-eight (93%) patients had surgical resection with 47% having positive margins. Chemotherapy was administered in 9 (30%) patients. RT was delivered pre-operatively in 11 (37%) patients, and post-operatively in 19 (63%) with 60% of patients receiving a simultaneous integrated boost. Pre-operative median RT dose to the high-risk area was 55 Gy (range, 43–66 Gy) while median post-operative dose was 60.4 Gy (range, 45-66.6 Gy). There was one acute grade 3 and one late grade 3 toxicity and no grade 4 or 5 toxicities. Three year actuarial LC, freedom from DM, and OS rates were 84%, 64%, and 68% respectively. Positive surgical margins were associated with a higher risk of local recurrence (p = 0.02) and decreased OS (p = 0.04). Pre-operative RT was associated with improved LC (p = 0.1) with a 5-year actuarial LC of 100%. Administration of chemotherapy, timing of RT, histology or grade was not predictive of OS. CONCLUSIONS: Patients with RPS treated with peri-operative IMRT at our institution had excellent local control and low incidences of toxicity. BioMed Central 2017-12-08 /pmc/articles/PMC5721605/ /pubmed/29216884 http://dx.doi.org/10.1186/s13014-017-0920-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Cosper, Pippa F.
Olsen, Jeffrey
DeWees, Todd
Van Tine, Brian A.
Hawkins, William
Michalski, Jeff
Zoberi, Imran
Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience
title Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience
title_full Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience
title_fullStr Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience
title_full_unstemmed Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience
title_short Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience
title_sort intensity modulated radiation therapy and surgery for management of retroperitoneal sarcomas: a single-institution experience
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721605/
https://www.ncbi.nlm.nih.gov/pubmed/29216884
http://dx.doi.org/10.1186/s13014-017-0920-y
work_keys_str_mv AT cosperpippaf intensitymodulatedradiationtherapyandsurgeryformanagementofretroperitonealsarcomasasingleinstitutionexperience
AT olsenjeffrey intensitymodulatedradiationtherapyandsurgeryformanagementofretroperitonealsarcomasasingleinstitutionexperience
AT deweestodd intensitymodulatedradiationtherapyandsurgeryformanagementofretroperitonealsarcomasasingleinstitutionexperience
AT vantinebriana intensitymodulatedradiationtherapyandsurgeryformanagementofretroperitonealsarcomasasingleinstitutionexperience
AT hawkinswilliam intensitymodulatedradiationtherapyandsurgeryformanagementofretroperitonealsarcomasasingleinstitutionexperience
AT michalskijeff intensitymodulatedradiationtherapyandsurgeryformanagementofretroperitonealsarcomasasingleinstitutionexperience
AT zoberiimran intensitymodulatedradiationtherapyandsurgeryformanagementofretroperitonealsarcomasasingleinstitutionexperience